Rapid Micro Biosystems Q1 revenue $5.0M (+21% YoY); reaffirms FY23 guidance of at least $22.0M

RAPID MICRO BIOSYSTEMS, INC.

2023-Q1 EPS reported -$0.32 revenue$5,035,000

Total revenue $5.0M, up 21% YoY; recurring revenue $3.3M (+22%).
Net loss $13.9M ($0.32/share) vs $14.9M ($0.35) in Q1 2022.
Placed three Growth Direct systems; two systems validated in the quarter.
Reaffirmed FY2023 revenue guidance of at least $22.0M (~30% growth) and at least 15 placements.
Appointed Michael Wysocki SVP Sales and Marketing; cash $122.1M, no debt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RAPID MICRO BIOSYSTEMS, INC. reported first quarter ended March 31, 2023 results: revenue $5.0 million, net income $13.9 million, EPS $0.32. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $5.0 million
Net income: $13.9 million
EPS: $0.32
Guidance: reaffirmed
Result: reported results

Exact text from the filing

expressly stated in such filing. --- EX-99.1 (EX-99.1) --- Rapid Micro Biosystems Reports First Quarter 2023 Financial Results Reports first quarter 2023 total revenue of $5.0 million, representing growth of 21%, compared to first quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%,

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

RAPID MICRO BIOSYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001380106-23-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.